Bildiri Koleksiyonu by Institution Author "Sevindik, Ömür Gökmen"
Now showing items 1-10 of 10
-
Adult case series of extramedullary relapsing acute myeloid leukemia (AML) after allogeneic stem cell transplantation in whom a rapid response and a reasonably long remission could be achieved with gemtuzumab ozogamycin (GO)
Sevindik, Ömür Gökmen; Gemici, Aliihsan; Usta, Furkan Selim; Çakır, Aslı; Sadri, Sevil; Bekoz, Hüseyin; Sargın, Fatma Deniz (The American Society of Hematology, 2019)Gemtuzumab Ozogamycin (GO) is a drug conjugated monoclonal antibody which targets CD33 an antigen highly expressed on the surface of AML blasts. GO is approved for the treatment of both newly-diagnosed and relapsed AML. ... -
Assesment of patient's perspective on treatment free remission in CML: A Turkish multicenter cohort
Mutlu, Yaşa Gül; Güvenç, Birol; Serin, İstemi; Balık Aydın, Berrin; Alacacıoğlu, İnci; Güven, Serkan; Sevindik, Ömür Gökmen (American Society of Hematology, 2022)Treatment free remission (TFR) is one of the main goals of therapy in Chronic Myeloid Leukemia (CML). Patient perspective and expectations have an indicative effect on discontinuation decisions. We analyzed 116 CML patients' ... -
Comparison of efficacy and safety of generic plerixafor vs original plerixafor in the mobilization of myeloma patients
Sevindik, Ömür Gökmen; Bilgen, Hülya; Serin, İstemi; Melek, Elif; Karakuş, Volkan; Çerçi, Kübra; Mutlu, Yaşa Gül; Balık Aydın, Berrin; Sadri, Sevil; Beköz, Hüseyin Saffet; Kaynar, Leylagül (American Society of Hematology, 2022)Introduction The commonest indication for an Autologous Stem Cell Transplantation (ASCT) is still Multiple Myeloma. A successful mobilization of hematopoietic stem cells (HSC) is a sine qua non of ASCT. The introduction ... -
Glofitamab in relapsed/refractory diffuse large B cell lymphoma: Real world data
Ferhanoğlu, Burhan; Gülbaş, Zafer; Uzay, Ant; Özcan, Muhit; Özkalemkaş, Fahir; Dal, Mehmet Sinan; Kalyon, Hakan; Akay, Olga Meltem; Deveci, Burak; Bekoz, Hüseyin; Sevindik, Ömür Gökmen; Toptaş, Tayfur; Yılmaz, Asu Fergün; Koyun, Derya; Alkış, Nihan; Birtaş Ateşoğlu, Elif (American Society of Hematology, 2022)Abstract INTRODUCT ̇ION Glofitamab is a T-cell-engaging bispecific antibody connecting CD20 on B cells and CD3 on T cells. Although, most of the patients with B-cell non-Hodgkin lymphoma (BNHL) achieve complete response ... -
An interim analysis of the Turkish myeloma registry among the patients who have received up to two lines of therapy
Sevindik, Ömür Gökmen; Özkurt, Zübeyde Nur; Boğa, Can; Kalayoğlu Beşışık, Sevgi; Yıldız, İpek; Gedük, Ayfer; Harmandali, Aybüke; Salihoğlu, Ayşe; Haydaroğlu Şahin, Handan; Sönmez, Mehmet; Vural, Filiz; Akay, Olga Meltem; Kurt Yüksel, Meltem; Maral, Senem; Ekinci, Ömer; Kırkızlar, Hakkı Onur; Tekinalp, Atakan; Demir, Nazlı; Merter, Mustafa; Saydam, Güray; Alacacıoğlu, İnci; Yeğin, Zeynep Arzu; Kaşar, Mutlu; Mastanzade, Metban; Özsan, Güner Hayri (American Society of Hematology, 2021)... -
Isatuximab in combination with lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma: Updated safety run-in results from the randomized phase 3 ithaca study
Mateos, Maria-Victoria; Rodriguez Otero, Paula; Koh, Youngil; Martinez-Lopez, Joaquin; Parmar, Gurdeep; Prince, H. Miles; Quach, Hang; Ribas, Paz; Hermansen, Emil; Hungria, Vania T. M.; Kalayoğlu Beşışık, Sevgi; Kim, Jin Seok; Leleu, Xavier; Peceliunas, Valdas; Schjesvold, Fredrik; Sevindik, Ömür Gökmen; Lavrova, Tatiana; Dubin, Franck; Devisme, Christine; Lepine, Lucie; Ghobrial, Irene (American Society of Hematology, 2022)Background: Results from a randomized, Phase 3 study by the Spanish Myeloma Group (PETHEMA/GEM) previously showed that treatment with lenalidomide plus dexamethasone (Rd) may delay progression to active disease in patients ... -
Retrospective analysis of Turkish AML registry database, on behalf of AML working group of Turkish society of hematology
Karakuş, Volkan; Sevindik, Ömür Gökmen; Karataş, Aylin; Yenihayat, Emel Merve; Polat, Merve Gökçen; Çelik, Serhat; Pınar, İbrahim Ethem; Alacacıoğlu, İnci (American Society of Hematology, 2022)Abstract Introduction: To investigate the demographics and treatment details of the acute myeloid leukemia (AML) patients who were diagnosed and followed up in Turkey. Methods: Patients who were recorded on the database ... -
Successful use of frontline daratumumab lenalidomide and dexamethasone in transplant ineligible frail patients with moderate renal failure at the time of presentation
Sevindik, Ömür Gökmen; Karakuş, Volkan (CIG Media Group, 2022)Introduction: Treatment of the elderly patients who have varying degrees of renal failure at the time of presentation, both due to the underlying plasma cell dyscrasia or the other comorbidities is a true challenge regarding ... -
Successful use of split dose intravenous daratumumab in an overweight multiple myeloma patient after first dose life threatening infusion-related reaction
Aykaş, Fatma; Karakuş, Volkan; Sevindik, Ömür Gökmen (CIG Media Group, 2022)Introduction: There is a paucity of data regarding the best practice to institute iv Daratumumab (D) in morbid obese patients regarding the infusion rate and duration, optimal dosing, and ideal way to cope with the infusion ... -
Turkish acute lymphoblastic leukemia registry, retrospective phase data
Demirkan, Fatih; Çiftçiler, Rafiye; Sevindik, Ömür Gökmen; Tekgündüz, Emre; Erkurt, Mehmet Ali; Vural, Filiz; Turgut, Burhan; Kaynar, Leylagül; Payzin, Kadriye Bahriye; Doğu, Mehmet Hilmi; Karakuş, Volkan; Altuntaş, Fevzi; Büyükaşık, Yahya (The American Society of Hematology, 2019)Background and Aim: Significant developments have occurred in clinical management of acute lymphoblastic leukemia (ALL) in adults over recent decades. However, treatment results are still not satisfactory especially in ...
